Key Risks that Alexion Pharmaceuticals Faces


Oct. 1 2015, Updated 9:08 a.m. ET

Key risks

In addition to research-related risks that the biotechnology sector has witnessed, individual biotechnology companies face additional risks due to their unique business models.

Article continues below advertisement

Business concentration risk

Alexion Pharmaceuticals (ALXN) depends on a single drug Soliris for most of its revenues. Alexion Pharmaceuticals continues to expand Soliris’s approved indications. The drug has been granted the orphan drug designation (or ODD) for various indications across the US, Europe, and Japan.

Currently, Soliris is one of the costliest drugs in the world and earns substantial revenues despite low patient volumes in the targeted rare diseases. However, with the governments in the world increasing their focus on reducing healthcare costs, an unexpected change in regulations can severely affect Alexion Pharmaceuticals’ profit margins. Change in demand as well as any research failure in Soliris’s label expansion will significantly impact Alexion’s business.

Biotechnology companies such as Biogen (BIIB), AbbVie (ABBV), and Regeneron (REGN) also have a similar business concentration risk.

Merger-related risks

Alexion Pharmaceuticals has acquired Synageva BioPharma for $8.4 billion. The deal has added two rare disease drugs, Kanuma and Strensiq, to Alexion’s portfolio. In addition, Alexion also expects to witness operating and tax-related synergies.

Alexion acquired Synageva Pharmaceuticals at a heavy premium of 140% to Synageva’s closing price on May 5, 2015. At such high valuations, if the expected synergies are not realized, it could lead to high losses for the combined entity.

Strategy risk

Alexion Pharmaceuticals is focused on providing innovative drugs for rare diseases. In the US, a rare disease is one that affects less than 200,000 people in the country. While there is more pricing flexibility for these rare disease drugs, they are also more sensitive to changes in demand and regulations as compared to mainstream drugs. Thus, Alexion’s unique focus on orphan drugs increases the level of revenue uncertainty for the company.

You can limit your exposure to Alexion Pharmaceuticals’ unique risks by investing in the iShares Nasdaq Biotechnology ETF (IBB). Alexion accounts for 5.07% of IBB’s total holdings.


More From Market Realist

  • SemiLEDS logo over LED lighting
    Company & Industry Overviews
    There's Still Time to Get in on SemiLEDS (LEDS) Stock
  • Trader on the NYSE
    Company & Industry Overviews
    What Are the Most Expensive Stocks Ever?
  • Michelob Ultra beer
    Company & Industry Overviews
    AB InBev Is the Top Beer Brand Worldwide—Is It a Monopoly?
  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.